What are the most valued startups in the longevity market?

Last updated: 13 July 2026

Download our beautiful pitch about the longevity market

market research pitch 2026 statistics longevity market

In our longevity market deck, you will find everything you need to understand the market

The longevity market brings together biotechnology, preventive healthcare, diagnostics, wearables, nutrition and services designed to extend healthy human lifespan.

This ranking tracks the most valuable longevity startups using reported valuations, public market capitalizations, acquisition prices and structured estimates.

We update this list every month to reflect new funding rounds, public market movements, acquisitions and changes in company performance.

And if you want to better understand this new industry, you can download our pitch covering the longevity market.

A quick summary table

Metric Value
Most valuable longevity startup Oura, $11.0B
Second most valuable longevity startup BioSplice Therapeutics, $8.0B–$12.0B
Median longevity startup valuation Approximately $90M
Share of longevity valuation captured by the top 10 Approximately 79%
Top longevity startup valuation vs. median Approximately 122 times
Median longevity valuation-to-capital-raised ratio Approximately 3.0 times
Longevity startups valued at $1B+ 10
Market map chart showing top companies and startups in the longevity market

This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market

Top startups in the longevity market ranked by valuation

Here is an updated table that ranks the top startups in the longevity market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the longevity market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Oura Smart ring health tracking $11.0B Full Confidence Announced Private Round Valuation Observed $1.2B Strong Confidence
2 BioSplice Therapeutics Alternative-splicing disease therapeutics $8.0B–$12.0B Partial Confidence Comparables-Based Estimate Estimated $778M Partial Confidence
3 Altos Labs Cellular rejuvenation therapeutics $4.5B–$6.5B Partial Confidence Comparables-Based Estimate Estimated $3.0B Full Confidence
4 Calico Life Sciences Aging biology drug research $3.0B–$5.0B Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
5 NewLimit Cellular reprogramming therapeutics $3.1B Full Confidence Announced Private Round Valuation Observed $682M Full Confidence
6 Insilico Medicine AI drug discovery platform $2.7B Full Confidence Public Market Cap Observed $811M Partial Confidence
7 Function Health Preventive health testing platform $2.5B Full Confidence Announced Private Round Valuation Observed $351M Full Confidence
8 Neko Health Preventive full-body health scans $1.6B–$2.0B Strong Confidence Announced Private Round Valuation Observed $325M Strong Confidence
9 Retro Biosciences Human healthspan therapeutics $1.6B–$2.0B Partial Confidence Active Raise Valuation Estimated $1.2B Partial Confidence
10 BioAge Labs Metabolic aging therapeutics $1.1B Full Confidence Public Market Cap Observed $607M Strong Confidence
11 Loyal Dog longevity drugs $700M–$1.1B Partial Confidence Implied Valuation from Raise Implied $250M Partial Confidence
12 Life Biosciences Cellular rejuvenation gene therapies $600M–$850M Strong Confidence Implied Valuation from Raise Implied $237M Strong Confidence
13 Alzheon Oral Alzheimer’s disease therapeutics $650M–$850M Partial Confidence Implied Valuation from Raise Estimated $206M Partial Confidence
14 Nura Bio Neuroprotective SARM1 inhibitor medicines $500M–$800M Strong Confidence Implied Valuation from Raise Implied $215M Full Confidence
15 Juvenescence Age-related disease therapeutics $500M–$800M Partial Confidence Implied Valuation from Raise Implied $290M Partial Confidence
16 Timeline Urolithin A longevity nutrition $430M–$700M Partial Confidence Implied Valuation from Raise Implied $73M Partial Confidence
17 Corsera Health Cardiovascular prevention RNA medicines $400M–$650M Strong Confidence Implied Valuation from Raise Implied $80M Full Confidence
18 Rejuveron Life Sciences Healthy-aging therapeutics platform $400M–$650M Partial Confidence Implied Valuation from Raise Implied $76M Partial Confidence
19 Gordian Biotechnology Age-related drug discovery platform $380M–$650M Partial Confidence Implied Valuation from Raise Implied $117M Partial Confidence
20 Viome Life Sciences Microbiome precision nutrition tests $350M–$550M Partial Confidence Comparables-Based Estimate Estimated $302M Partial Confidence
21 Blueprint Consumer longevity protocol platform $300M–$500M Partial Confidence Implied Valuation from Raise Implied $60M Strong Confidence
22 Cambrian Bio Longevity therapeutics portfolio $300M–$500M Partial Confidence Comparables-Based Estimate Estimated $211M Partial Confidence
23 Illimis Therapeutics Neuroimmune biologic therapies $280M–$440M Partial Confidence Implied Valuation from Raise Implied $57M Partial Confidence
24 Nuritas AI-discovered therapeutic food peptides $280M–$450M Strong Confidence Implied Valuation from Raise Implied $110M Strong Confidence
25 L-Nutra Fasting-mimicking nutrition programs $280M–$430M Strong Confidence Implied Valuation from Raise Implied $84M Strong Confidence
26 SciNeuro Pharmaceuticals Neurodegeneration drug developer $270M–$440M Partial Confidence Implied Valuation from Raise Implied $153M Full Confidence
27 Everlab AI preventive healthcare $310M–$340M Strong Confidence Announced Private Round Valuation Observed $58M Strong Confidence
28 Liom Non-invasive metabolic biomarker wearables $240M–$400M Partial Confidence Implied Valuation from Raise Implied $48M Partial Confidence
29 Human Longevity Genomics preventive health services $250M–$310M Partial Confidence Comparables-Based Estimate Estimated $370M Strong Confidence
30 Aeovian Pharmaceuticals Selective mTORC1 therapeutics $220M–$360M Partial Confidence Implied Valuation from Raise Implied $88M Full Confidence
31 Arda Therapeutics Targeted cell depletion therapies $220M–$320M Partial Confidence Implied Valuation from Raise Implied $43M Full Confidence
32 Cellular Origins Robotic cell therapy manufacturing $200M–$330M Partial Confidence Implied Valuation from Raise Implied Not provided Low Confidence
33 Neurable Consumer brain-computer interface wearables $175M–$290M Strong Confidence Implied Valuation from Raise Implied $65M Partial Confidence
34 Jocasta Neuroscience a-Klotho cognitive therapies $175M–$290M Strong Confidence Implied Valuation from Raise Implied $35M Strong Confidence
35 Rubedo Life Sciences Senescent-cell therapeutics platform $180M–$280M Partial Confidence Implied Valuation from Raise Implied $52M Full Confidence
36 MindImmune Therapeutics Neuroinflammation Alzheimer’s therapies $150M–$250M Partial Confidence Implied Valuation from Raise Implied $30M Partial Confidence
37 Amplifier Therapeutics AMPK drugs for aging diseases $150M–$240M Partial Confidence Implied Valuation from Raise Implied $33M Full Confidence
38 Fountain Life Preventive longevity health centers $140M–$240M Partial Confidence Implied Valuation from Raise Implied $52M Partial Confidence
39 Minovia Therapeutics Mitochondrial augmentation therapies $160M–$220M Partial Confidence IPO or Listing Range Valuation Observed $28M Partial Confidence
40 resTORbio Aging-related disease therapeutics $170M Full Confidence Acquisition Value Observed $163M Full Confidence
41 Turn Biotechnologies Cellular reprogramming RNA medicines $110M–$190M Partial Confidence Comparables-Based Estimate Estimated $30M Partial Confidence
42 Alkahest Plasma-derived aging therapeutics $146M Full Confidence Acquisition Value Observed $41M Strong Confidence
43 Thymmune Therapeutics Regenerative thymic cell therapies $140M Full Confidence Acquisition Value Observed $7M Strong Confidence
44 Elysium Health Longevity supplements and biomarkers $100M–$180M Low Confidence Revenue or ARR Multiple Estimate Estimated $26M Partial Confidence
45 Gero AI aging drug discovery $100M–$170M Strong Confidence Implied Valuation from Raise Implied $34M Partial Confidence
46 Junevity Cell reset therapeutics startup $80M–$130M Partial Confidence Implied Valuation from Raise Implied $20M Strong Confidence
47 Tolerance Bio Thymus-based immune therapies $80M–$125M Strong Confidence Implied Valuation from Raise Implied $35M Strong Confidence
48 LyGenesis Lymph-node organ regeneration therapies $90M–$150M Partial Confidence Implied Valuation from Raise Implied $22M Strong Confidence
49 Elevian GDF11 regenerative medicines $90M–$160M Low Confidence Comparables-Based Estimate Estimated $61M Full Confidence
50 Oisin Biotechnologies Genetic medicines targeting aging $65M–$105M Partial Confidence Implied Valuation from Raise Estimated $25M Partial Confidence
51 Neuraly Neurodegenerative disease therapeutics $50M–$90M Low Confidence Proxy-Based Estimate Estimated $36M Strong Confidence
52 Grey Matter Neurosciences Alzheimer’s ultrasound headset $56M–$93M Strong Confidence Implied Valuation from Raise Implied $14M Full Confidence
53 Shift Bioscience AI cellular rejuvenation discovery $60M–$95M Partial Confidence Implied Valuation from Raise Estimated $29M Partial Confidence
54 Booster Therapeutics Proteasome activator drug development $55M–$90M Partial Confidence Implied Valuation from Raise Estimated $15M Full Confidence
55 Repair Biotechnologies Atherosclerosis reversal therapies $60M–$95M Partial Confidence Implied Valuation from Raise Implied $26M Partial Confidence
56 Biograph Premium preventive diagnostics clinics $40M–$90M Low Confidence Comparables-Based Estimate Estimated Not provided Low Confidence
57 Amphix Bio Regenerative supramolecular peptide therapeutics $50M–$85M Strong Confidence Implied Valuation from Raise Implied $13M Partial Confidence
58 Radar Therapeutics Programmable RNA therapeutics $50M–$85M Partial Confidence Implied Valuation from Raise Implied $13M Full Confidence
59 Vincere Biosciences Parkinson’s mitochondrial therapeutics $25M–$60M Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
60 Acorn Biolabs Personal stem-cell preservation services $35M–$60M Partial Confidence Implied Valuation from Raise Implied $8M Strong Confidence
61 Edifice Health Inflammatory age testing platform $35M–$65M Low Confidence Comparables-Based Estimate Estimated $14M Strong Confidence
62 Rejuvenation Technologies mRNA therapies targeting aging $35M–$50M Partial Confidence Comparables-Based Estimate Estimated $11M Full Confidence
63 Epiterna Aging-slowing therapeutics discovery $35M–$50M Low Confidence Comparables-Based Estimate Estimated $11M Full Confidence
64 Deciduous Therapeutics Senescent-cell immunotherapies $35M–$55M Partial Confidence Comparables-Based Estimate Estimated $16M Partial Confidence
65 Biopeak Longevity clinics and diagnostics $35M–$55M Partial Confidence Implied Valuation from Raise Implied $7M Strong Confidence
66 Morphoceuticals Bioelectric regenerative medicine platform $40M–$65M Partial Confidence Comparables-Based Estimate Estimated $15M Partial Confidence
67 Circulate Health Therapeutic plasma exchange longevity $48M–$80M Strong Confidence Implied Valuation from Raise Implied $12M Strong Confidence
68 Modulo Bio Neuroimmune drug discovery platform $35M–$55M Partial Confidence Comparables-Based Estimate Estimated $13M Partial Confidence
69 NaNotics Disease-targeting nanomedicine platform $30M–$55M Low Confidence Comparables-Based Estimate Estimated $10M Partial Confidence
70 GlycanAge Glycan biological age diagnostics $35M–$60M Partial Confidence Implied Valuation from Raise Implied $13M Strong Confidence
71 Rejuvenate Bio Gene therapies for aging diseases $30M–$50M Strong Confidence Implied Valuation from Raise Implied $16M Strong Confidence
72 MitoRx Therapeutics Mitochondrial obesity therapeutics $32M–$48M Strong Confidence Implied Valuation from Raise Implied $12M Strong Confidence
73 Cyclarity Therapeutics Oxidized cholesterol removal therapeutics $30M–$42M Strong Confidence Announced Private Round Valuation Estimated $24M Strong Confidence
74 AgelessRx Longevity telehealth prescriptions $28M–$45M Partial Confidence Revenue or ARR Multiple Estimate Estimated $8M Partial Confidence
75 Tomorrow Bio Human cryopreservation services $22M–$36M Strong Confidence Implied Valuation from Raise Implied $6M Full Confidence
76 Vasa Therapeutics Cardiovascular aging therapeutics $24M–$40M Low Confidence Implied Valuation from Raise Implied $6M Strong Confidence
77 SENISCA RNA senotherapeutics for aging $20M–$35M Low Confidence Implied Valuation from Raise Implied $9M Strong Confidence
78 Generation Lab Longevity diagnostics platform $50M–$80M Partial Confidence Implied Valuation from Raise Implied Not provided Low Confidence
79 Matter Bio Genome integrity therapeutics $25M–$45M Partial Confidence Implied Valuation from Raise Implied $7M Strong Confidence
80 BE Therapeutics Brain tissue replacement therapies $18M–$35M Low Confidence Proxy-Based Estimate Estimated $6M Low Confidence
81 Biolytica AI longevity clinic platform $20M–$35M Low Confidence Comparables-Based Estimate Estimated $6M Strong Confidence
82 Cyclana Bio Endometriosis tissue drug discovery $27M–$45M Strong Confidence Implied Valuation from Raise Implied $7M Strong Confidence
83 clock.bio Stem-cell rejuvenation drug discovery $20M–$32M Partial Confidence Implied Valuation from Raise Estimated $5M Full Confidence
84 Tally Health Consumer epigenetic age testing $15M–$30M Low Confidence Acquisition Value Estimated $10M Full Confidence
85 NADMED NAD blood testing $18M–$32M Partial Confidence Implied Valuation from Raise Implied $4M Strong Confidence
86 Cirrus Therapeutics Therapeutics startup, limited disclosure $20M–$35M Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
87 Genflow Biosciences SIRT6 gene therapies $20M Full Confidence Public Market Cap Observed $7M Partial Confidence
88 Celularity Cell therapy biotech company $19M Full Confidence Public Market Cap Observed $582M Full Confidence
89 Longevica Longevity research and therapeutics $20M–$45M Low Confidence Proxy-Based Estimate Estimated $16M Partial Confidence
90 Mito Health AI preventive-health testing clinic $9M–$15M Partial Confidence Revenue or ARR Multiple Estimate Estimated $4M Partial Confidence
91 NOVOS Longevity supplements and age tools $9M–$14M Partial Confidence Comparables-Based Estimate Estimated $3M Strong Confidence
92 ImmuneAge Bio Immune stem-cell rejuvenation platform $8M–$15M Low Confidence Implied Valuation from Raise Estimated $2M Strong Confidence
93 Bionic Health Personalized preventive health clinic $8M–$15M Low Confidence Acquisition Value Estimated $3M Strong Confidence
94 Decode Age Longevity diagnostics and supplements $8M–$10M Strong Confidence Announced Private Round Valuation Estimated $2M Partial Confidence
95 Leucadia Therapeutics Alzheimer’s fluid-drainage device $3M–$10M Low Confidence Proxy-Based Estimate Estimated Not provided Low Confidence
96 Deep Longevity AI biological aging clocks $4M Full Confidence Acquisition Value Observed Not provided Low Confidence
97 UNITY Biotechnology Senolytic disease therapeutics $3M Full Confidence Public Market Cap Observed $297M Strong Confidence
98 CohBar Mitochondrial-peptide therapeutics shell $1M–$2M Partial Confidence Public Market Cap Observed $63M Partial Confidence
Chart comparing the 2026 size of the longevity market with other markets of similar size

This chart, featured in our longevity market deck, compares the 2026 size of the longevity market with other markets of similar size

Key valuation trends in the longevity market

Insights

  • Consumer longevity platforms can be more capital efficient than drug developers. Oura’s $11.0B valuation is more than nine times its $1.2B funding base.
  • The ten largest longevity startups capture approximately four-fifths of the market’s combined valuation, showing how strongly capital and perceived value are concentrated at the top.
  • Preventive healthcare is becoming a major longevity category. Function Health, Neko Health and Everlab have a combined valuation of about $4.6B after raising approximately $734M.
  • Nutrition-focused longevity companies can scale without traditional pharmaceutical spending. Nuritas and L-Nutra have combined valuation midpoints near $720M on approximately $194M in funding.
  • Public market results remain highly asymmetric. BioAge Labs is valued near $1.1B, while Celularity and UNITY Biotechnology are worth about $22M combined after raising approximately $879M.
  • Strategic acquisitions have produced very different outcomes. Thymmune’s $140M acquisition value equaled twenty times its funding, while resTORbio’s $170M transaction value was close to its total capital raised.
  • Corsera Health, Jocasta Neuroscience and Everlab each reached estimated valuation-to-funding multiples above five times, despite operating in very different parts of the longevity market.
  • Early longevity companies can create meaningful value with limited capital. Circulate Health, MitoRx Therapeutics and Cyclana Bio raised $31M combined and have combined valuation midpoints of approximately $140M.
Chart showing Function Health’s strategy in the longevity market

This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity

A few word about our methodology

As you can see, we built a database that ranks startups in the longevity market based on their current valuation.

Estimating longevity startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company, business model and development stage.

To build this longevity market ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a longevity company is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a longevity startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, subscriber growth, clinical progress or customer traction, combined with valuation multiples from comparable companies.

The most relevant comparison group depends on the business. A clinical biotechnology company cannot be valued in the same way as a preventive healthcare platform, wearable, diagnostic service or nutrition brand.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, clinical milestones, regulatory progress or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by public market data, acquisition prices, strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because longevity valuation data is not always fully public, each startup in the ranking is assigned a confidence level based on the reliability, recency and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the longevity market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Chart showing the projected CAGR of the longevity market

This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups

Related blog posts

- The most recent news in the longevity market

- The most recent funding news in the longevity market

- The latest developments shaping the longevity market

- The evolution of funding activity in the longevity market

- The main fundraising trends in the longevity market

- How large is the longevity market in reality?

- The full range of business models in the longevity market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog